Literature DB >> 14687705

Enhancement of a human immunodeficiency virus env DNA vaccine using a novel polycationic nanoparticle formulation.

Christopher P Locher1, David Putnam, Robert Langer, Stephanie A Witt, Brittany M Ashlock, Jay A Levy.   

Abstract

In an effort to develop a more effective DNA immunization strategy for HIV, we synthesized an HIV-2 env DNA vaccine and delivered it in a novel polycationic adjuvant formulation that forms nanoparticles in solution and enhances protein expression. The polycationic adjuvant contained imidazole moieties to facilitate endosomal escape. Nanoparticles containing the DNA vaccine plasmid were formed by electrostatic condensation with the polycationic adjuvant. We hypothesized that this formulation would improve immune responses to the gp140 env gene from HIV-2(UC2) by increasing the level of expressed antigen. We found that the nanoparticles were superior at inducing high levels of systemic antibody responses compared to naked DNA when delivered by the intradermal route in BALB/c mice. In addition, the nanoparticles induced higher levels of IgM, IgG, and IgA antibodies. These results suggest that nanoparticles may be an important adjuvant formulation to improve the effectiveness of genetic immunization and rationalize its use in the evaluation of vaccine candidates in non-human primate models for AIDS.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14687705     DOI: 10.1016/j.imlet.2003.02.001

Source DB:  PubMed          Journal:  Immunol Lett        ISSN: 0165-2478            Impact factor:   3.685


  10 in total

1.  Quantum effect on the energy levels of Eu2+ doped K2Ca2(SO4)3 nanoparticles.

Authors:  Numan Salah; Sami S Habib; Zishan H Khan
Journal:  J Fluoresc       Date:  2010-04-13       Impact factor: 2.217

2.  Well-defined block copolymers for gene delivery to dendritic cells: probing the effect of polycation chain-length.

Authors:  Rupei Tang; R Noelle Palumbo; Lakshmi Nagarajan; Emily Krogstad; Chun Wang
Journal:  J Control Release       Date:  2009-10-27       Impact factor: 9.776

3.  Electroporation mediated DNA vaccination directly to a mucosal surface results in improved immune responses.

Authors:  Gleb Kichaev; Janess M Mendoza; Dinah Amante; Trevor R F Smith; Jay R McCoy; Niranjan Y Sardesai; Kate E Broderick
Journal:  Hum Vaccin Immunother       Date:  2013-06-11       Impact factor: 3.452

4.  Poly(2-aminoethyl methacrylate) with well-defined chain length for DNA vaccine delivery to dendritic cells.

Authors:  Weihang Ji; David Panus; R Noelle Palumbo; Rupei Tang; Chun Wang
Journal:  Biomacromolecules       Date:  2011-11-16       Impact factor: 6.988

5.  Effect of solid lipid nanoparticles formulation compositions on their size, zeta potential and potential for in vitro pHIS-HIV-hugag transfection.

Authors:  Rathapon Asasutjarit; Sven-Iver Lorenzen; Sunee Sirivichayakul; Kiat Ruxrungtham; Uracha Ruktanonchai; Garnpimol C Ritthidej
Journal:  Pharm Res       Date:  2007-03-24       Impact factor: 4.200

6.  Polymeric Materials for Gene Delivery and DNA Vaccination.

Authors:  David N Nguyen; Jordan J Green; Juliana M Chan; Robert Longer; Daniel G Anderson
Journal:  Adv Mater       Date:  2008-12-04       Impact factor: 30.849

Review 7.  Nanotechnology: intelligent design to treat complex disease.

Authors:  Patrick Couvreur; Christine Vauthier
Journal:  Pharm Res       Date:  2006-06-21       Impact factor: 4.580

8.  Non-human papillomaviruses for gene delivery in vitro and in vivo.

Authors:  Lea Bayer; Jessica Gümpel; Gerd Hause; Martin Müller; Thomas Grunwald
Journal:  PLoS One       Date:  2018-06-18       Impact factor: 3.240

Review 9.  Mitochondrion: A Promising Target for Nanoparticle-Based Vaccine Delivery Systems.

Authors:  Ru Wen; Afoma C Umeano; Lily Francis; Nivita Sharma; Smanla Tundup; Shanta Dhar
Journal:  Vaccines (Basel)       Date:  2016-06-01

Review 10.  Targeting the porcine immune system--particulate vaccines in the 21st century.

Authors:  Kenneth C McCullough; Artur Summerfield
Journal:  Dev Comp Immunol       Date:  2008-09-02       Impact factor: 3.636

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.